Retina

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.

While the potential for fundus images is recognized, the methodology and clinical application must be improved.

According to the company, favorable safety and tolerability profiles were observed with the first 2 SPVN06 doses across 6 patients. The exploration of SPVN06 in geographic geographic atrophy is set to begin in 2024.

Genetic testing is proving to be an evolving technology for ophthalmologists.

Two retina specialists participated in an Ophthalmology Times case-based roundtable discussion and shared their experiences using the anti-VEGF biosimilars, ranibizumab-eqrn and ranibizumab-nuna to manage retinal diseases.

David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.

Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases at the Retina 2024 meeting in Maui.

According to the company, all three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

Catch up on a few of Modern Retina's top stories and ones you may have missed in 2023

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

Scientists have developed a versatile imaging system that will help diagnose pathologies in the eye fundus.

During a multidisciplinary meeting with FDA, based on preliminary results from an ongoing Phase 1/2 study, the company received alignment on key points of the Phase 3 study design.

Inaugural awards honor 3 residents in ophthalmology, optometry, and retina

Ocugen says the Regenerative Medicine Advanced Therapy designation will "help expedite the development of new regenerative medicines."

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

The kidney and eye are structurally and functionally similar, and the diseases of the organs may present similarly and via common pathways.

LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.

ROP can be a disease that affects both the retinal and choroidal vasculatures.

David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.

Dilsher Dhoot, MD, presents two cases involving DME and CRVO, that show remarkable anatomical improvement with a biosimilar comparable to those achieved with reference biologics.

Dilsher Dhoot, MD, provides an overview of biosimilars in retinal diseases and discusses how he identifies patients suitable for biosimilar therapy.

The company has come into agreement with IQVIA Services Japan G.K. as well as AUROLAB.

Fish have the built-in ability to regenerate retinal neurons by turning another retinal cell type called Müller glia into neurons. Researchers have been able to coax the human Müller glia into changing identity in the laboratory, which could serve as a potential source of new neurons to treat vision loss.

According to the company, ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatment.

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

This retrospective, cross-sectional study identified all inpatients diagnosed with syphilitic uveitis in the US between 2010 and 2019.